Publication: 3748

Publication: 3748

Daratumumab (DARA) + lenalidomide, bortezomib, and dexamethasone (RVd) in transplant-eligible newly diagnosed multiple myeloma (NDMM): a post hoc analysis of sustained minimal residual disease (MRD) negativity from GRIFFIN (AFT-29)

DOI

URL

Google Scholar

Citation:: J Clin Oncol vol 40 (16_suppl) 8011

Meeting Instance:: ASCO 2022
Year:: 2022
Type:: Abstract
Sub type:: Poster Discussion
Funding:: AFT
Endpoint:: Secondary-not-in-original
Analysis:: Primary
Data Sharing:: No-Data-Sharing
Status:: Presented/Published
Citation Status:: epub

Note:

Methodological:: No
Biospecimen:: No
SDC:: No

Parents:: None
Children:: 3854

Program:: OGC
Primary Committee:: Myeloma
Sec. Committees:

Pharmas:: JNJ
Grants:

Corr. Author:
Authors:: Cesar Rodriguez Jonathan L. Kaufman Jacob Laubach Douglas W. Sborov Brandi Reeves Ajai Chari Rebecca Silbermann Luciano J. Costa Larry D. Anderson Jr Nitya Nathwani Nina Shah Naresh Bumma Andrzej Jakubowiak Robert Z. Orlowski Huiling Pei Annelore Cortoos Sharmila Patel Thomas S. Lin Paul G. Richardson Peter M. Voorhees

Networks:: CA043, CA824, LAPS-AL002, LAPS-IL057, LAPS-MA036, LAPS-NC007, LAPS-OH007, LAPS-TX011, LAPS-TX035, LAPS-UT003, NC002, NY021, OR013

Study: AFT-29 (GRIFFIN)
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:: 2

Keywords: